CBIO Q4 2025 Earnings — Crescent Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

CBIOCrescent Biopharma, Inc.

$345M

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$11M

Gross Profit

$11M99.5% margin

Operating Income

-$103M-952.8% margin

Net Income

-$92M-852.1% margin

EPS (Diluted)

$-4.58

QoQ Revenue Growth

-64.5%

Cash Flow

Operating Cash Flow

$22M

Free Cash Flow

$22M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$240M

Total Liabilities

$37M

Stockholders' Equity

$203M

Cash & Equivalents

$213M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11M	$0	—
Gross Profit	$11M	$27,043	+39799.4%
Operating Income	-$103M	-$36M	-186.5%
Net Income	-$92M	-$7M	-1179.2%

Revenue Segments

Reportable Segment

$8M100%